세계의 안지오텐신 수용체 차단제(ARB) 시장 보고서(2023년)

“Angiotensin Receptor Blockers (ARBs) Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on angiotensin receptor blockers (arbs) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for angiotensin receptor blockers (arbs) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The angiotensin receptor blockers (arbs) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product: Valsartan; Telmisartan; Losartan; Irbesartan; Azilsartan; Olmesartan

• 2) By Application: Hypertension; Cardiovascular Diseases; Kidney Diseases; Other Applications

• 3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers

• Companies Mentioned: Pfizer Inc.; Novartis AG; Merck & Co. Inc.; AstraZeneca Plc.; Bristol-Myers Squibb Company

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GSK Plc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy's Laboratories Ltd., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., Lupin Pharmaceuticals Inc., Astellas Pharma Inc., and Boehringer Ingelheim Ltd.

The global angiotensin receptor blockers (ARBs) market is expected to grow from $8.02 billion in 2022 to $8.30 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The angiotensin receptor blockers (ARBs) market is expected to grow to $9.40 billion in 2027 at a CAGR of 3.2%.

The angiotensin receptor blockers (ARBs) market consists of sales of candesartan and eprosartan. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Angiotensin receptor blockers (ARBs) are medications that dilate (widen) blood vessels and are used to treat conditions such as high blood pressure (hypertension), heart failure, and kidney disease in people with diabetes. Angiotensin is a chemical in the body that causes blood vessels to constrict. This constriction can raise the blood pressure and make the heart work harder.

North America was the largest region in the angiotensin receptor blockers (ARBs) market in 2022. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main products of angiotensin receptor blockers (ARBs) include valsartan, losartan, irbesartan, azilsartan and olmesartan. Losartan is an angiotensin receptor blocker that lowers the risk of stroke while treating hypertension and diabetic nephropathy. Their various applications include hypertension, cardiovascular diseases, kidney diseases, and others for use by end-users such as hospitals, specialty clinics, and ambulatory surgical centers.

The increasing incidence of cardiovascular diseases is expected to propel the growth of the angiotensin receptor blockers market going forward. Cardiovascular disease (CVD) is any condition affecting the heart or blood vessels. It is frequently associated with the development of fatty deposits within the arteries (atherosclerosis) and an increased risk of blood clots. By assisting in vein and artery relaxation, angiotensin receptor blockers lower blood pressure and facilitate the heart's ability to pump blood, which can reduce cardiovascular diseases. For instance, in October 2022, according to the report published by the Centers for Disease Control and Prevention, a US-based international organization responsible for public health, in 2020, over 697,000 people in the United States died from heart disease, accounting for one out of every five deaths. Therefore, the increasing incidence of cardiovascular diseases is driving the growth of the angiotensin receptor blockers market.

Product innovation is a key trend in gaining popularity in the angiotensin receptor blockers market. Major companies operating in the angiotensin receptor blocker market are focused on developing innovative solutions to strengthen their position in the market. For instance, in February 2021, Novartis AG, a Switzerland-based pharmaceutical company, launched Entresto (sacubitril/valsartan). Entresto (sacubitril/valsartan) has been granted an expanded indication by the United States Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. The clinical benefits are most noticeable in patients with a lower-than-normal left ventricular ejection fraction (LVEF). Entresto is the first and only therapy approved in the United States to treat patients with guideline-defined heart failure, which includes both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF).

The increase in the prevalence of hypertension diseases is expected to propel the growth of the angiotensin receptor blockers (ARBs) market going forward. Hypertension, often known as high or rising blood pressure, is a disorder characterized by chronically elevated blood vessel pressure. Angiotensin receptor blockers (ARBs) are a type of medication that is commonly used to treat hypertension. They primarily function by relaxing and widening the blood arteries, giving the blood greater room to pass through. Thus, increasing hypertension diseases among people will increase the demand for angiotensin receptor blockers. For instance, in October 2022, according to an article published by the Centers for Disease Control and Prevention, a US-based international organization responsible for public health, hypertension was a primary or contributing cause of about 670,000 deaths in the United States in 2020. Hypertension affects nearly half of all adults in the United States (47%, or 116 million). Only around one in every four persons (24%) has hypertension under control. Around 34 million persons who have been advised to take medication may require it to be prescribed and started. Almost two-thirds of this population (19 million) has a blood pressure of 140/90 mmHg or higher. Therefore, the increase in the prevalence of hypertension diseases is driving the growth of the angiotensin receptor blockers (ARBs) market.

The countries covered in the angiotensin receptor blockers (ARBs) market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The angiotensin receptor blockers (ARBs) market research report is one of a series of new reports from The Business Research Company that provides angiotensin receptor blockers (ARBs) market statistics, including angiotensin receptor blockers (ARBs) industry global market size, regional shares, competitors with a angiotensin receptor blockers (ARBs) market share, detailed angiotensin receptor blockers (ARBs) market segments, market trends and opportunities, and any further data you may need to thrive in the angiotensin receptor blockers (ARBs) industry. This angiotensin receptor blockers (ARBs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Angiotensin Receptor Blockers (ARBs) Market Characteristics

3. Angiotensin Receptor Blockers (ARBs) Market Trends And Strategies

4. Angiotensin Receptor Blockers (ARBs) Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Angiotensin Receptor Blockers (ARBs) Market
• 4.2. Ukraine-Russia War Impact On Angiotensin Receptor Blockers (ARBs) Market
• 4.3. Impact Of High Inflation On Angiotensin Receptor Blockers (ARBs) Market

5. Angiotensin Receptor Blockers (ARBs) Market Size And Growth

• 5.1. Global Angiotensin Receptor Blockers (ARBs) Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Angiotensin Receptor Blockers (ARBs) Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Angiotensin Receptor Blockers (ARBs) Market Segmentation

• 6.1. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Valsartan
• Telmisartan
• Losartan
• Irbesartan
• Azilsartan
• Olmesartan
• 6.2. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hypertension
• Cardiovascular Diseases
• Kidney Diseases
• Other Applications
• 6.3. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

7. Angiotensin Receptor Blockers (ARBs) Market Regional And Country Analysis

• 7.1. Global Angiotensin Receptor Blockers (ARBs) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Angiotensin Receptor Blockers (ARBs) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market

• 8.1. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Angiotensin Receptor Blockers (ARBs) Market

• 9.1. China Angiotensin Receptor Blockers (ARBs) Market Overview
• 9.2. China Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Angiotensin Receptor Blockers (ARBs) Market

• 10.1. India Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Angiotensin Receptor Blockers (ARBs) Market

• 11.1. Japan Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Angiotensin Receptor Blockers (ARBs) Market

• 12.1. Australia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Angiotensin Receptor Blockers (ARBs) Market

• 13.1. Indonesia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Angiotensin Receptor Blockers (ARBs) Market

• 14.1. South Korea Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Angiotensin Receptor Blockers (ARBs) Market

• 15.1. Western Europe Angiotensin Receptor Blockers (ARBs) Market Overview
• 15.2. Western Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Angiotensin Receptor Blockers (ARBs) Market

• 16.1. UK Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Angiotensin Receptor Blockers (ARBs) Market

• 17.1. Germany Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Angiotensin Receptor Blockers (ARBs) Market

• 18.1. France Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market

• 19.1. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market Overview
• 19.2. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Angiotensin Receptor Blockers (ARBs) Market

• 20.1. Russia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Angiotensin Receptor Blockers (ARBs) Market

• 21.1. North America Angiotensin Receptor Blockers (ARBs) Market Overview
• 21.2. North America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Angiotensin Receptor Blockers (ARBs) Market

• 22.1. USA Angiotensin Receptor Blockers (ARBs) Market Overview
• 22.2. USA Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Angiotensin Receptor Blockers (ARBs) Market

• 23.1. South America Angiotensin Receptor Blockers (ARBs) Market Overview
• 23.2. South America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Angiotensin Receptor Blockers (ARBs) Market

• 24.1. Brazil Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Angiotensin Receptor Blockers (ARBs) Market

• 25.1. Middle East Angiotensin Receptor Blockers (ARBs) Market Overview
• 25.2. Middle East Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Angiotensin Receptor Blockers (ARBs) Market

• 26.1. Africa Angiotensin Receptor Blockers (ARBs) Market Overview
• 26.2. Africa Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape And Company Profiles

• 27.1. Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape
• 27.2. Angiotensin Receptor Blockers (ARBs) Market Company Profiles
  • 27.2.1. Pfizer Inc.
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Novartis AG
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Merck & Co. Inc.
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. AstraZeneca Plc.
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Bristol-Myers Squibb Company
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Angiotensin Receptor Blockers (ARBs) Market

29. Angiotensin Receptor Blockers (ARBs) Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer